Therapeutic modulation of prostate cancer metastasis

被引:7
|
作者
Krishna, Sankar N. [1 ]
Bergan, Raymond C. [1 ,2 ,3 ]
机构
[1] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA
[2] Northwestern Univ, Ctr Mol Innovat & Drug Discovery, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
CIRCULATING TUMOR-CELLS; HUMAN MONOCLONAL-ANTIBODY; ENDOTHELIAL GROWTH-FACTOR; I KINASE INHIBITOR; TGF-BETA; PHASE-I; OSTEOCLAST DIFFERENTIATION; MATRIX METALLOPROTEINASES; SIGNALING PATHWAY; ZOLEDRONIC ACID;
D O I
10.4155/fmc.13.201
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Targeting prostate cancer metastasis has very high therapeutic potential. Prostate cancer is the second most common cause of cancer death among men in the USA, and death results from the development of metastatic disease. In order to metastasize, cancer cells must complete a series of steps that together constitute the metastatic cascade. Each step therefore offers the opportunity for therapeutic targeting. However, practical limitations have served as limiting roadblocks to successfully targeting the metastatic cascade. They include our still-emerging understanding of the underlying biology, as well as the fact that many of the dysregulated processes have critical functionality in otherwise normal cells. We provide a discussion of the underlying biology, as it relates to therapeutic targeting. Therapeutic inroads are rapidly being made, and we present a series of case studies to highlight key points. Finally, future perspectives related to drug discovery for antimetastatic agents are discussed.
引用
收藏
页码:223 / 239
页数:17
相关论文
共 50 条
  • [21] Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis
    Park, Sun H.
    Keller, Evan T.
    Shiozawa, Yusuke
    CALCIFIED TISSUE INTERNATIONAL, 2018, 102 (02) : 152 - 162
  • [22] Autophagy provides a conceptual therapeutic framework for bone metastasis from prostate cancer
    YouZhi Wang
    Ning Wu
    Ning Jiang
    Cell Death & Disease, 12
  • [23] Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer
    Kim, SJ
    Uehara, H
    Yazici, S
    He, JQ
    Langley, RR
    Mathew, P
    Fan, D
    Fidler, IJ
    CANCER RESEARCH, 2005, 65 (09) : 3707 - 3715
  • [24] Breast metastasis of prostate cancer
    Hsieh, C
    Chen, MY
    Chen, FH
    Chiu, JF
    XXXIII WORLD CONGRESS OF THE INTERNATIONAL COLLEGE OF SURGEONS - ICS 2002, 2002, : 235 - 238
  • [25] Metastasis suppression in prostate cancer
    Jaeger, EB
    Samant, RS
    Rinker-Schaeffer, CW
    CANCER AND METASTASIS REVIEWS, 2001, 20 (3-4) : 279 - 286
  • [26] CLUE TO METASTASIS IN PROSTATE CANCER
    SCOTT, WW
    GERIATRICS, 1971, 26 (10) : 46 - &
  • [27] Subdural Metastasis of Prostate Cancer
    Nzokou, Andre
    Magro, Elsa
    Guilbert, Francois
    Fournier, Jean Yves
    Bojanowski, Michel W.
    JOURNAL OF NEUROLOGICAL SURGERY REPORTS, 2015, 76 (01) : 123 - 127
  • [28] Bone metastasis in prostate cancer
    Moltzahn, F.
    Thalmann, G. N.
    UROLOGE, 2012, 51 (01): : 20 - +
  • [29] Breast metastasis of prostate cancer
    Hsieh, CM
    Chen, MY
    Chen, FH
    Chiu, JF
    BREAST JOURNAL, 2005, 11 (01): : 78 - 78
  • [30] Prostate Cancer Metastasis to the Stomach
    Hong, Kyoung Pyo
    Lee, Seong Ju
    Hong, Geun Sik
    Yoon, Hana
    Shim, Bong Suk
    KOREAN JOURNAL OF UROLOGY, 2010, 51 (06) : 431 - 433